Cox-2 inhibitors and cardiovascular risk: we defend our data and suggest caution.
Mukherjee
D
D
Division of Cardiology, University of Michigan Health System, Ann Arbor, University Hospital, 48103-0022, USA. dmukherj@umich.edu
Nissen
S E
SE
Topol
E J
EJ
D000075202:Contraindications; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D004359:Drug Therapy, Combination; D011464:Epoprostenol / Q000096:biosynthesis; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D008565:Membrane Proteins; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000453:epidemiology; D011451:Prostaglandin-Endoperoxide Synthases; D016032:Randomized Controlled Trials as Topic; D012107:Research Design
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D011464:Epoprostenol; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases